Type 1 Diabetes and Dysfunctional Intestinal Homeostasis

Trends in Endocrinology and Metabolism

Volumn 27, Issue 7, 2016, Pages 493-503

  D'Addio, Francesca ^a,b   Fiorina, Paolo ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Circulating enterotrophic hormones; Diabetic enteropathy; Gastrointestinal disorders; Intestinal stem cells

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CORTICOSTEROID; CYTOKINE; DIPHENOXYLATE; GASTROINTESTINAL HORMONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOPERAMIDE; METFORMIN; METHOTREXATE; NEUROTRANSMITTER; OCTREOTIDE; USTEKINUMAB;

AUTONOMIC NEUROPATHY; DIABETIC ENTEROPATHY; DIAGNOSTIC TEST; ENTEROPATHY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINAL STEM CELL; INTESTINE FLORA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; REVIEW; ANIMAL; COMPLICATION; CYTOLOGY; GASTROINTESTINAL DISEASE; INTESTINE; METABOLISM; STEM CELL;

ANIMALS; DIABETES MELLITUS, TYPE 1; GASTROINTESTINAL DISEASES; HUMANS; INTESTINES; STEM CELLS;

EID: 84966716353     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.04.005     Document Type: Review

References (90)

1. Katz L.A., Spiro H.M. Gastrointestinal manifestations of diabetes. N. Engl. J. Med. 1966, 275:1350-1361.
2. Feldman M., Schiller L.R. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann. Internal Med. 1983, 98:378-384.
3. Ko G.T., et al. Gastrointestinal symptoms in Chinese patients with type 2 diabetes mellitus. Diabetic Med. 1999, 16:670-674.
4. Bytzer P., et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch. Internal Med. 2001, 161:1989-1996.
5. Bytzer P., et al. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am. J. Gastroenterol. 2002, 97:604-611.
6. Talley N.J., et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am. J. Gastroenterol. 2001, 96:71-76.
7. Kempler P., et al. Gastrointestinal autonomic neuropathy in diabetes: the unattended borderline between diabetology and gastroenterology. Diabetologia 2016, 59:401-403.
8. von der Ohe M.R. Diarrhoea in patients with diabetes mellitus. Eur. J. Gastroenterol. Hepatol. 1995, 7:730-736.
9. Ordog T. Interstitial cells of Cajal in diabetic gastroenteropathy. Neurogastroenterol. Motil. 2008, 20:8-18.
10. Koch K.L. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and treatment. Dig. Dis. Sci. 1999, 44:1061-1075.
11. Rayner C.K., et al. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001, 24:371-381.
12. Vinik A.I., et al. Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553-1579.
13. Anitha M., et al. GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J. Clin. Invest. 2006, 116:344-356.
14. Chandrasekharan B., et al. Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol. Motil. 2011, 23:131-138.
15. Holst J.J., et al. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 2011, 27:547-558.
16. Latorre R., et al. Enteroendocrine cells: a review of their role in brain-gut communication. Neurogastroenterol. Motil. 2016, 28:620-630.
17. Fiorina P., et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 2003, 26:1129-1136.
18. Mawe G.M., Hoffman J.M. Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:473-486.
19. Huizinga J.D., et al. Physiology, injury, and recovery of interstitial cells of Cajal: basic and clinical science. Gastroenterology 2009, 137:1548-1556.
20. Strid H., et al. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol. Dial. Transplant. 2002, 17:1434-1439.
21. Vaarala O., et al. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008, 57:2555-2562.
22. Vaarala O. Human intestinal microbiota and type 1 diabetes. Curr. Diabetes Rep. 2013, 13:601-607.
23. Horvath V.J., et al. Diabetes-related dysfunction of the small intestine and the colon: focus on motility. Curr. Diabetes Rep. 2015, 15:94.
24. Domenech A., et al. Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFNbeta transgenic mice. Int. J. Exp. Pathol. 2011, 92:400-412.
25. Itoh H., et al. Regeneration of injured intestinal mucosa is impaired in hepatocyte growth factor activator-deficient mice. Gastroenterology 2004, 127:1423-1435.
26. Wang C.L., et al. In vivo characterization of intestinal effects of endomorphin-1 and endomorphin-2 in type 1 diabetic mice. Eur. J. Pharmacol. 2013, 698:499-504.
27. Medema J.P., Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 2011, 474:318-326.
28. Jung P., et al. Isolation and in vitro expansion of human colonic stem cells. Nat. Med. 2011, 17:1225-1227.
29. Harding J.L., et al. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care 2015; 38: 264-270. Diabetes Care 2015, 38:734-735.
30. Yuhara H., et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. Am. J. Gastroenterol. 2011, 106:1911-1921. quiz 1922.
31. Teng J.A., et al. The activation of ERK1/2 and JNK MAPK signaling by insulin/IGF-1 is responsible for the development of colon cancer with type 2 diabetes mellitus. PLoS ONE 2016, 11:e0149822.
32. Cheng C.W., Yilmaz O.H. IGFBP3 and T1D: systemic factors in colonic stem cell function and diabetic enteropathy. Cell Stem Cell 2015, 17:379-380.
33. Thomas H. Diabetes: circulating factors implicated in diabetic enteropathy. Nat. Rev. Endocrinol. 2015, 11:688.
34. Thomas H. Diabetes: circulating factors implicated in diabetic enteropathy. Nat. Rev. Gastroenterol. Hepatol. 2015, 12:671.
35. D'Addio F., et al. Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy. Cell Stem Cell 2015, 17:486-498.
36. Svedlund J., et al. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 1988, 33:129-134.
37. Talley N.J., et al. A patient questionnaire to identify bowel disease. Ann. Internal Med. 1989, 111:671-674.
38. Carrington E.V., et al. Traditional measures of normal anal sphincter function using high-resolution anorectal manometry (HRAM) in 115 healthy volunteers. Neurogastroenterol. Motil. 2014, 26:625-635.
39. Portincasa P., et al. Assessing gastrointestinal symptoms and perception, quality of life, motility, and autonomic neuropathy in clinical studies. J. Gastrointest. Liver Dis. 2009, 18:205-211.
40. Yantiss R.K., Odze R.D. Optimal approach to obtaining mucosal biopsies for assessment of inflammatory disorders of the gastrointestinal tract. Am. J. Gastroenterol. 2009, 104:774-783.
41. Eliakim R., Magro F. Imaging techniques in IBD and their role in follow-up and surveillance. Nat. Rev. Gastroenterol. Hepatol. 2014, 11:722-736.
42. Robertson D.J., Imperiale T.F. Stool testing for colorectal cancer screening. Gastroenterology 2015, 149:1286-1293.
43. Wright E.K., et al. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm. Bowel Dis. 2014, 20:1668-1677.
44. Yang Z., et al. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin. Gastroenterol. Hepatol. 2014, 12:253-262.
45. Stoddard P.B., et al. Magnetic resonance enterography: state of the art. Inflamm. Bowel Dis. 2015, 21:229-239.
46. Corsetti M., et al. The quest for biomarkers in IBS-where should it lead us?. Neurogastroenterol. Motil. 2014, 26:1669-1676.
47. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329:977-986.
48. Bytzer P., et al. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment. Pharmacol. Ther. 2001, 15:137-142.
49. Valdovinos M.A., et al. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clinic Proc. 1993, 68:691-702.
50. Mourad F.H., et al. Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide. Gut 1992, 33:1578-1580.
51. D'Addio F., et al. Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes. Diabetes Care 2014, 37:267-276.
52. Fiorina P., et al. Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. Diabetes 2004, 53:2291-2300.
53. Fiorina P., et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003, 75:1296-1301.
54. Folli F., et al. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. PLoS ONE 2010, 5:e9923.
55. Danese S., Panes J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 2014, 147:981-989.
56. Carter M.J., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004, 53(Suppl. 5):V1-V16.
57. Schonhoff S.E., et al. Minireview: development and differentiation of gut endocrine cells. Endocrinology 2004, 145:2639-2644.
58. D'Mello S., et al. Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis. Inflamm. Bowel Dis. 2012, 18:236-245.
59. Kundu P., et al. An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth. Sci. Transl. Med. 2015, 7:281ra244.
60. Merlos-Suarez A., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8:511-524.
61. Piscaglia A.C., et al. Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease. J. Transl. Med. 2015, 13:220.
62. Beyaz S., et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature 2016, 531:53-58.
63. Yilmaz O.H., et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 2012, 486:490-495.
64. Tavakkolizadeh A., et al. Tissue-engineered neomucosa: morphology, enterocyte dynamics, and SGLT1 expression topography. Transplantation 2003, 75:181-185.
65. Avansino J.R., et al. Orthotopic transplantation of intestinal mucosal organoids in rodents. Surgery 2006, 140:423-434.
66. + stem cell. Nat. Med. 2012, 18:618-623.
67. Watson C.L., et al. An in vivo model of human small intestine using pluripotent stem cells. Nat. Med. 2014, 20:1310-1314.
68. Sato T., Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 2013, 340:1190-1194.
69. Sato T., et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011, 141:1762-1772.
70. Dekkers J.F., et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat. Med. 2013, 19:939-945.
71. Wiegerinck C.L., et al. Loss of syntaxin 3 causes variant microvillus inclusion disease. Gastroenterology 2014, 147:65-68.
72. Okamoto R., Watanabe M. Perspectives for regenerative medicine in the treatment of inflammatory bowel diseases. Digestion 2015, 92:73-77.
73. Dedhia P.H., et al. Organoid models of human gastrointestinal development and disease. Gastroenterology 2016, 150:1098-1112.
74. Lee S.H., et al. Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors. Cancer Lett. 2015, 367:34-42.
75. Bartfeld S., et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology 2015, 148:126-136.
76. Zhang Y.G., et al. Salmonella-infected crypt-derived intestinal organoid culture system for host-bacterial interactions. Physiol. Rep. 2014, 2:e12147.
77. Leushacke M., Barker N. Ex vivo culture of the intestinal epithelium: strategies and applications. Gut 2014, 63:1345-1354.
78. Fridell J.A., et al. The pancreas allograft donor: current status, controversies, and challenges for the future. Clin. Transplant. 2010, 24:433-449.
79. Goldberg D.S., et al. Increasing the number of organ transplants in the United States by optimizing donor authorization rates. Am. J. Transplant. 2015, 15:2117-2125.
80. Margreiter C., et al. Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type-2 diabetes mellitus. Transplantation 2013, 95:1030-1036.
81. D'Addio F., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes 2014, 63:3041-3046.
82. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N. Engl. J. Med. 1997, 336:633-640.
83. Enck P., et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z. Gastroenterol. 1994, 32:637-641.
84. Gersemann M., et al. From intestinal stem cells to inflammatory bowel diseases. World J. Gastroenterol. 2011, 17:3198-3203.
85. Senger S., et al. Celiac disease histopathology recapitulates hedgehog downregulation, consistent with wound healing processes activation. PLoS ONE 2015, 10:e0144634.
86. Boman B.M., Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J. Clin. Oncol. 2008, 26:2828-2838.
87. Zhao J., et al. Biomechanical and morphometric intestinal remodelling during experimental diabetes in rats. Diabetologia 2003, 46:1688-1697.
88. Alam C., et al. Inflammatory tendencies and overproduction of IL-17 in the colon of young NOD mice are counteracted with diet change. Diabetes 2010, 59:2237-2246.
89. Graham S., et al. Enteropathy precedes type 1 diabetes in the BB rat. Gut 2004, 53:1437-1444.
90. Secondulfo M., et al. Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. Dig. Liver Dis. 2004, 36:35-45.